Open Access Research

Magnetic core-shell nanoparticles for drug delivery by nebulization

Navin Kumar Verma12*, Kieran Crosbie-Staunton12, Amro Satti23, Shane Gallagher23, Katie B Ryan4, Timothy Doody4, Colm McAtamney2, Ronan MacLoughlin5, Paul Galvin6, Conor S Burke7, Yuri Volkov12 and Yurii K Gun’ko23

  • * Corresponding author: Navin Kumar Verma verman@tcd.ie

  • † Equal contributors

Author Affiliations

1 Department of Clinical Medicine, Institute of Molecular Medicine, Trinity College Dublin, Dublin, Ireland

2 Centre for Research on Adaptive Nanostructures and Nanodevices, Trinity College Dublin, Dublin, Ireland

3 Department of Chemistry, Trinity College Dublin, Dublin, Ireland

4 School of Pharmacy, University College Cork, Cork, Ireland

5 Aerogen, Galway Business Park, Dangan, Galway, Ireland

6 Tyndall National Institute, University College Cork, Cork, Ireland

7 Dublin City University, Dublin, Ireland

For all author emails, please log on.

Journal of Nanobiotechnology 2013, 11:1  doi:10.1186/1477-3155-11-1

Published: 23 January 2013

Abstract

Background

Aerosolized therapeutics hold great potential for effective treatment of various diseases including lung cancer. In this context, there is an urgent need to develop novel nanocarriers suitable for drug delivery by nebulization. To address this need, we synthesized and characterized a biocompatible drug delivery vehicle following surface coating of Fe3O4 magnetic nanoparticles (MNPs) with a polymer poly(lactic-co-glycolic acid) (PLGA). The polymeric shell of these engineered nanoparticles was loaded with a potential anti-cancer drug quercetin and their suitability for targeting lung cancer cells via nebulization was evaluated.

Results

Average particle size of the developed MNPs and PLGA-MNPs as measured by electron microscopy was 9.6 and 53.2 nm, whereas their hydrodynamic swelling as determined using dynamic light scattering was 54.3 nm and 293.4 nm respectively. Utilizing a series of standardized biological tests incorporating a cell-based automated image acquisition and analysis procedure in combination with real-time impedance sensing, we confirmed that the developed MNP-based nanocarrier system was biocompatible, as no cytotoxicity was observed when up to 100 μg/ml PLGA-MNP was applied to the cultured human lung epithelial cells. Moreover, the PLGA-MNP preparation was well-tolerated in vivo in mice when applied intranasally as measured by glutathione and IL-6 secretion assays after 1, 4, or 7 days post-treatment. To imitate aerosol formation for drug delivery to the lungs, we applied quercitin loaded PLGA-MNPs to the human lung carcinoma cell line A549 following a single round of nebulization. The drug-loaded PLGA-MNPs significantly reduced the number of viable A549 cells, which was comparable when applied either by nebulization or by direct pipetting.

Conclusion

We have developed a magnetic core-shell nanoparticle-based nanocarrier system and evaluated the feasibility of its drug delivery capability via aerosol administration. This study has implications for targeted delivery of therapeutics and poorly soluble medicinal compounds via inhalation route.

Keywords:
Nanomedicine; Magnetite nanoparticles; Quercetin; Drug delivery; Nebulization